JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258767

Human ZMPSTE24 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

ZMPSTE24 KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.

View Alternative Names

CAAX prenyl protease 1 homolog, FACE1_HUMAN, Farnesylated proteins-converting enzyme 1, Prenyl protein-specific endoprotease 1, STE24, Zinc metalloproteinase Ste24 homolog

1 Images
Sanger Sequencing - Human ZMPSTE24 knockout HeLa cell lysate (AB258767)
  • Sanger seq

Unknown

Sanger Sequencing - Human ZMPSTE24 knockout HeLa cell lysate (AB258767)

Homozygous : 1 bp insertion in exon 1

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.

Disease

Adenocarcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258767-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human ZMPSTE24 knockout HeLa cell lysate", "number":"AB258767-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB258767-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ZMPSTE24
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ZMPSTE24 also known as FACE1 or STE24 is a zinc metalloprotease enzyme involved in the post-translational modification of prelamin A to mature lamin A. This enzyme specifically cleaves the C-terminal tail of prelamin A a critical step required for proper nuclear envelope structure and function. ZMPSTE24 has a molecular mass of approximately 54 kDa and is expressed in several tissues including skeletal muscle heart and skin. Its activity primarily takes place in the endoplasmic reticulum membrane where it executes its proteolytic functions.
Biological function summary

The alteration of prelamin A to lamin A by ZMPSTE24 is necessary for maintaining nuclear shape and stability. Lamin A is a major component of the nuclear lamina providing structural support to the nuclear envelope. ZMPSTE24 is part of a proteolytic complex that ensures the proper maturation of lamin A which plays a significant role in DNA replication and cellular division. Deficiency in ZMPSTE24 activity can lead to the accumulation of farnesylated prelamin A disrupting nuclear architecture and cellular processes.

Pathways

The function of ZMPSTE24 integrates into the broader context of the lamin A maturation pathway significant for nuclear integrity. It collaborates with other enzymes like farnesyltransferase and icmt during the maturation process of prelamin A to lamin A. ZMPSTE24 also interacts with the protein lamin B which is an associate in the nuclear lamina. This cooperation within the pathway ensures the functional execution of nuclear mechanical properties and DNA repair processes.

The abnormal function or mutation of ZMPSTE24 connects direly with disorders such as restrictive dermopathy and Hutchinson-Gilford progeria syndrome (HGPS). In HGPS defective ZMPSTE24 fails to process prelamin A leading to the build-up of a toxic version of prelamin A termed progerin. This accumulation contributes to premature aging phenotypes. The disorder correlates with mutations in LMNA a gene encoding lamins A and C highlighting the tandem dependency between ZMPSTE24 and lamin A in maintaining nuclear structure and overall cellular health.

Quality control

STR analysis

D13S317, D7S820, D5S818, TH01, D16S539, TPOX, CSF1PO

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com